The approval of CAR T-cell therapy for paediatric leukaemia marks an important shift in the blood cancer treatment paradigm, the President of the American Society of Haematology says. Novartis’s therapy is approved to treat children and young adults with relapsed acute lymphoblastic leukaemia and will be marketed as tisagenlecleucel (Kymriah). In response to the FDA approval ASH ...
Paradigm shift for aggressive blood cancers
6 Sep 2017